-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $40

Benzinga·04/02/2026 13:51:50
Listen to the news
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $46 to $40.